Ali Raza Khaki (Stanford)
95% of new oncology drugs approved in US before Europe in past decade, study finds
Ali Raza Khaki is a bladder cancer doctor at Stanford. He’s seen five immune checkpoint inhibitors approved as a second line of treatment, but he really only uses one for that indication — pembrolizumab, marketed as Keytruda, since it’s the only one with randomized controlled trial data.
Two of the other inhibitors, AstraZeneca’s Imfinzi and Roche’s Tecentriq, have since had their accelerated approvals for bladder cancer pulled by the FDA (or rather, the Big Pharmas ‘voluntarily withdrew’ them).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
